



Model List of Essential Medicines



Abacavir [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (as sulfate)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Didanosine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
- Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Emtricitabine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 10 mg per mL
- Oral > Solid: 200 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Lamivudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid: 150 mg tablet

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Stavudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Liquid: 5 mg per 5 mL powder for oral solution
- Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)



Tenofovir disoproxil fumarate [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#) [Contact with or exposure to human immunodeficiency virus](#)



Zidovudine [General information](#)

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

- Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
- Oral > Liquid: 50 mg per 5 mL
- Oral > Solid > tablet: 300 mg
- Oral > Solid > capsule: 250 mg

Indications

[Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified](#)